biopharma-reporter1h
FDA approves Pfizer's antibody treatment for hemophilia
The approval of Hympavzi makes it the first treatment for both hemophilia A and B to be administered through a pre-filled pen ...
WebMD11h
New Hemophilia Drug Helps Prevent Bleeding Episodes
The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.
Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi
Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be ...
Pharmaceutical Technology19h
ENHERTU gains conditional approval in China to treat NSCLC
Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's NMPA for a specific type of NSCLC.
Pharmaceutical Technology19h
Capricor touts long-term efficacy of DMD therapy ahead of FDA application
Capricor Therapeutics plans to apply for FDA approval for its DMD cell therapy, deramiocel, by the end of 2024.
Pharmabiz20h
Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors
Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 18:00 Hrs [IST] Pfizer ...
FDA approves Pfizer’s HYMPAVZI to treat haemophilia
HYMPAVZI is the first and only approved anti-tissue factor pathway inhibitor in the US for haemophilia A or B treatment.